Chapter

Hyperglycemia- and Hyperlipidemia-Induced Inflammation and Oxidative Stress through Human T Lymphocytes and Human Aortic Endothelial Cells (HAEC)

Frankie B. Stentz

Abstract

Approximately 65% of patients with T2DM die as a result of cardiovascular disease with hyperglycemia and hyperlipidemia being important risk factors for cardiovascular diseases. Both T2DM and atherosclerosis are considered to be inflammatory processes. Human T-lymphocytes (T-cells) and aortic endothelial cells (HAEC) have been shown to be components of plaque formation in atherosclerosis. T cells and HAEC are unique in that in their naive state they have no insulin receptors responsive to insulin but become activated in vitro hyperglycemia and in vivo hyperglycemic conditions such as diabetic ketoacidosis and non-ketotic hyperglycemic conditions. Our studies show that T-cells and HAEC in the presence of high concentrations of glucose and/or the saturated fatty acid (SFA) palmitic acid become activated and express insulin receptors, reactive oxygen species (ROS), cytokine elevation, and lipid peroxidation in a time and concentration-dependent manner. Whereas, the unsaturated fatty acid α-linoleic, was not able to activate these cells and had a salutary effect on the activation by glucose and palmitic acid. We have demonstrated that unsaturated fatty acids (UFA) may provide a protective mechanism against the prooxidant effects of hyperglycemia and high SFA such as palmitic acid. Therefore, diet alternations may be beneficial for decreasing hyperglycemia and cardiovascular risks. Studies have shown that lifestyle changes of diet and exercise can reduce the risk of developing diabetes by 58%. Hyperglycemia and hyperlipidemia are important risk factors of developing diabetes and cardiovascular disease. Therefore, we studied the effects of a High Protein diet versus a High Carbohydrate diet in obese non-diabetic, prediabetic and diabetic subjects for effects on weight loss, blood sugar, lipid levels, inflammation, and oxidative stress.

Keywords: blood glucose, free fatty acids, insulin sensitivity, inflammation, cardiovascular risk factors, T lymphocytes, human aortic endothelial cells (HAEC), high protein diet (HP), high carbohydrate diet (HC)
1. Introduction

Greater than 65% of patients with Type 2 Diabetes Mellitus (T2DM) die as a result of cardiovascular disease with hyperglycemia and hyperlipidemia being important risk factors for cardiovascular diseases [1]. Studies have shown that glucose control results in reduction in risk of microvascular complications in diabetes mellitus [2]. The relationship between hyperglycemia and macrovascular complications, however, is not as evident even though subjects with T2DM are two to four times more prone to develop cardiovascular pathology than nondiabetic subjects [3, 4]. Hyperglycemia is a crucial factor contributing to vascular impairment in diabetes mellitus, obesity, and metabolic syndrome [2, 5–7]. Evidence indicates that in hyperglycemic conditions a major contributor to development of large vessel pathology is the endothelial dysfunction [8–10]. Studies have shown that hyperglycemia impairs insulin induced vasodilatory action by decreasing endothelial cells ability to activate nitric oxide synthase-nitric oxide pathway [11]. In hyperglycemic crisis of Diabetic Ketoacidosis (DKA) or hyperglycemic nonketotic state, where both hyperglycemia and high fatty acids are elevated, levels of proinflammatory cytokines and oxidative stress are stimulated [12].

Both T2DM and atherosclerosis are considered to be inflammatory processes [13]. Human T-lymphocytes (T-cells) have been shown to be components of plaque formation along with endothelial cells in atherosclerosis [13]. Human T-lymphocytes have unique properties in that in their naïve state they are insulin unresponsive but upon exposure to high glucose levels they become activated and develop insulin receptors (INR) with emergence of insulin degrading enzyme and insulin responsive glucose uptake [14–19]. Our studies have shown that reactive oxygen species (ROS) along with proinflammatory cytokines such as: Tumor Necrosis Factor α (TNF-α), Interleukin-6 (IL-6), Interleukin-1β (IL-1β) and Interleukin-8 (IL-8); cardiovascular risk markers such as: PAI-1, CRP and Free Fatty Acids (FFA); and counterregulatory hormones such as: IGF-1 and cortisol were all elevated two to three fold above normal with hyperglycemia and returned to normal levels after resolution of hyperglycemia with treatment with insulin and hydration [12]. Our studies have also shown in vitro effects of hyperglycemia (15 and 30 mM) on activation of T-lymphocytes by emergence of IGF-1, INR and Vitamin D receptors and increased levels of ROS and lipid peroxidation [15–18, 20].

Human aortic endothelial cells (HAEC) are also unique in that in their native unstimulated state of glucose of 5 mM they are insulin non-responsive, with GLUT1 as the major glucose transporting protein [21–23]; however, in the presence of high glucose concentrations in a dose dependent manner such as 15 or 30 mM, develop INR and GLUT 4 with glucose uptake [24]. Additionally, high glucose promotes endothelial dysfunction via excessive intracellular glucose accumulation and oxidative stress, leading to increased production proinflammatory cytokines, ROS with induction of the aldose reductase pathway and formation of advanced glycation end products (AGEs) as well as enhanced signaling of protein kinase C (PKC) and mitogen-activated protein kinases (MAPK) [8, 25]. The ROS causes acceleration of cellular growth and promotes synthesis and secretion of proinflammatory cytokines IL-6 and IL-8 which are implicated in the pathogenesis of atherosclerosis [24, 26, 27].

2. Inflammation and oxidative stress effects of glucose and fatty acids on human T-lymphocytes and HAEC

Since both hyperglycemia and hyperlipidemia are important contributing risk for cardiovascular events in diabetes and deleterious effects of hyperglycemia have
been well documented in vivo and in vitro in both T-lymphocytes and HAEC [12, 15, 17, 19, 20, 28–30], we studied the effects of various fatty acids on these cells. The saturated fatty acid palmitic acid, the major fatty acid in plasma, and the monounsaturated, oleic (C18:1), polyunsaturated fatty acids, linoleic (C18:2), omega 3 fatty acid α-linolenic (C18:3), and arachidonic (C20:4) acids were used in 1, 100 and 300 uM concentrations during incubations for 0, 24, 48, 72 and 96 hours. These cells were incubated alone or with glucose concentrations of 5 mM, 15 mM and 30 mM or with a combination with linolenic acid. Unsaturated fatty acids such as linoleic, oleic, linolenic, and arachidonic acids were not able to activate these cells. These studies showed that palmitic acid, but not oleic, linoleic, linolenic or arachidonic acids, exhibited dose and time dependent responses of deleterious effects of palmitic acid by demonstrating increased levels of ROS and lipid peroxidation (malondialdehyde- MDA), emergence of receptors for insulin, IGF-1, IL-2, GLUT 4, inflammatory and proinflammatory effects detected by the emergence of interleukin (IL) cytokines IL-1B, IL-6, IL-8, IL-2, IL-10, and TNFα and CD69 in T lymphocytes [31]. There was also increased expression of E-selectin, GLUT 4, INR, ROS, lipid peroxidation, inflammatory and proinflammatory effects detected by the emergence of interleukin (IL) cytokines IL-1B, IL-6, IL-8, IL-2, IL-10, and TNFα in the HAEC incubated with palmitic acid and/or glucose. Table 1 shows the effects of the glucose, palmitic and linolenic incubated alone or in combination with the T lymphocytes. The omega 3 fatty acid linolenic acid had a repressive effect on the deleterious effects of the high glucose and palmitic acid. Table 2 shows the effects of the glucose, palmitic and linolenic incubated alone or in combination with the HAEC. The omega 3 fatty acid linolenic acid had a repressive effect on the deleterious effects of the high glucose and palmitic acid in the HAEC as well.

Studies have shown that dietary SFA can induce insulin resistance [32–35]. We hypothesized that unsaturated fatty acids (UFA) may provide a protective mechanism against the prooxidant effects of hyperglycemia and high SFA such as palmitic acid. Our studies have also shown that SFA palmitic acid induces expression of GPR40 and FATCD/36 involved in inflammation and the unsaturated fatty acid linolenic acid can reverse the production of these receptors in aortic endothelial cells [36].

Thus, linolenic acid may serve as a protective mechanism against the deleterious effects of high glucose and palmitate in human T-cells and HAEC and reduce the inflammatory process observed with high blood glucose and high saturated fatty acid foods as observed in diabetes, prediabetes, cardiovascular disease and other health conditions.

3. High protein and high carbohydrate diets effects on remission of prediabetes, inflammation, oxidative stress and cardiovascular risk factors

Lifestyle changes of diet and exercise can reduce the risk of developing diabetes by 58% [37]; whereas, pharmaceutical intervention reduces the risk by 32% (metformin) [37] and 72% (pioglitazone) [38]. Hyperglycemia and hyperlipidemia are important risk factors of developing diabetes and cardiovascular disease; however, no diet had been established for reducing the hyperglycemia and hyperlipidemia. Although numerous diets have been recommended for T2DM and non-diabetics [39–43], and suggested advantages of low-carbohydrate [44, 45] or high protein [46, 47] diets, there had been no consensus on a specific weight loss diet to manage blood glucose in T2DM and converting from T2DM to normal glucose tolerance. We studied the effects of macronutrients in a High Protein (HP) (30% Kcal protein,
|                      | Glucose (G) | Palmitic acid (P) | Linolenic acid (L) | G (15 mM) + P (100 μM) | G (15 mM) + L (100 μM) | G (15 mM) + P (100 μM) + L (100 μM) |
|----------------------|-------------|-------------------|-------------------|------------------------|------------------------|--------------------------------------|
| **Activation markers** |             |                   |                   |                        |                        |                                      |
| CD69 (%)             | <1          | 11 ± 7’           | 26 ± 3’           | <1                     | 2 ± 1’                 | 3 ± .8’                              |
|                      | <1          | 1 <1               | <1                | 14 ± 2’                | 4 ± .6’                | 6 ± 1.7’                             |
| INSR (%)             | 0           | 5 ± 1’             | 12 ± 2’           | 0                      | 8 ± 2’                 | 14 ± 2’                              |
|                      | 0           | 0                  | 0                 | 12 ± 2’                | 2 ± .6’                | 5 ± 2’                               |
| CD25 (%)             | 0           | 6 ± 1’             | 17 ± 3’           | 0                      | 10 ± 2’                | 18 ± 3’                              |
|                      | 0           | 0                  | 0                 | 15 ± 3’                | 3 ± .5’                | 6.5 ± .4’                            |
| **Oxidative stress** |             |                   |                   |                        |                        |                                      |
| DCF (%)              | 0           | 7 ± 1.2’           | 23 ± 2’           | 1 ± .3                 | 14 ± 2’                | 30 ± 3’                              |
|                      | 0           | 0                  | 0                 | 21 ± 3’                | 4 ± .5’                | 8 ± 2’                               |
| TBA (MDA)            | 0           | 6 ± 2’             | 19 ± 4’           | .8 ± .1                | 10 ± 2’                | 22 ± 3’                              |
|                      | 0           | 0                  | 0                 | 15 ± 2’                | 3 ± 1’                 | 9 ± 1’                               |
| **Inflammation**     |             |                   |                   |                        |                        |                                      |
| TNFα (pg/ml)         | 7 ± 1       | 36 ± 2’            | 185 ± 4’          | 7 ± 1                  | 71 ± 3’                | 98 ± 3’                              |
|                      | 16 ± 1      | 51 ± 2’            | 21 ± 2’           | 3 ± 1                  | 21 ± 2’                | 34 ± 2’                              |
|                      | 3 ± 1       | 41 ± 1’            | 3 ± 1             | 29 ± 3’                | 11 ± 1’                | 17 ± 2’                              |
| IL-1β (pg/ml)        | 6 ± 1       | 43 ± 2’            | 171 ± 3’          | 6 ± 2                  | 58 ± 3’                | 87 ± 3’                              |
|                      | 6 ± 2       | 7 ± 2              | 6 ± 2             | 62 ± 2                 | 27 ± 3’                | 71 ± 3’                              |
| IL-6 (pg/ml)         | 12 ± 2      | 184 ± 3’           | 215 ± 5’          | 10 ± 2                 | 78 ± 3’                | 102 ± 4’                             |
|                      | 9 ± 2       | 9 ± 2              | 9 ± 2             | 235 ± 6’               | 83 ± 3’                | 118 ± 3’                             |
| IL-2 (pg/ml)         | 23 ± 2      | 69 ± 3’            | 172 ± 4’          | 23 ± 3                 | 87 ± 4’                | 119 ± 3’                             |
|                      | 23 ± 2      | 24 ± 3             | 23 ± 2            | 153 ± 4’               | 36 ± 3’                | 89 ± 2’                              |
| IL-10 (pg/ml)        | 9 ± 1       | 20 ± 2’            | 69 ± 3’           | 9 ± 2                  | 34 ± 3’                | 58 ± 3’                              |
|                      | 9 ± 2       | 9 ± 2              | 9 ± 2             | 47 ± 3’                | 12 ± 1’                | 29 ± 3’                              |
| **Inflammation inhibition with NFkBi** | |                   |                   |                        |                        |                                      |
| TNFα + NFkBi         | 6 ± 1       | 6 ± 1              | 6 ± 2             | 5 ± 1                  | 5 ± 2                  | 6 ± 2                                |
|                      | 5 ± 1       | 5 ± 1              | 5 ± 1             | 5 ± 1                  | 5 ± 1                  | 5 ± 1                                |
|                      | 7 ± 2       | 7 ± 2              | 7 ± 3             |                        |                        |                                      |

Values indicate mean ± SE. Measured at 72 hours.

*P < 0.05 from baseline.

†p < 0.05 from glucose (15 mM) or palmitate (100 μM).

Δp < 0.05 from glucose (15 mM) + palmitate (100 μM).

**Table 1.**

Effect of glucose, palmitic acid, and α-linolenic acid on activation of human T cells, proinflammatory cytokines and IL-10 and oxidative stress (DCF and MDA) at 72 hrs of incubation.
| Glucose (G)     | Palmitic Acid (P) | Linolenic Acid (L) | G (15 mM) + P (100 μM) | G (15 mM) + L (100 μM) | G (15 mM) + P (100 μM) + L (100 μM) |
|-----------------|-------------------|--------------------|-------------------------|------------------------|--------------------------------------|
| 5 mM            | 15 mM             | 30 mM              | 5 μM                    | 100 μM                 | 300 μM                               |
| E-Selectin%     | <1                | 24 ± 4t             | 39 ± 3t                 | <1                     | 18 ± 3t                              |
|                 |                   | 37 ± 3t             | 42 ± 4t                 | <1                     | 42 ± 3t                              |
|                 |                   | <1                  | 8 ± 2t                  | <1                     | 8 ± 2t                               |
|                 |                   | 10 ± 3t             | 22 ± 3t                 | <1                     | 16 ± 3t                              |
|                 |                   | <1                  | 8 ± 2t                  | <1                     | 6 ± 2t                               |
|                 |                   | 3 ± 1               | 8 ± 2t                  | <1                     | 22 ± 3t                              |
|                 |                   | 3 ± 1               | 6 ± 2t                  | <1                     | 21 ± 3t                              |
|                 |                   | 3 ± 1               | 13 ± 3t                 | <1                     | 8 ± 2t                               |
|                 |                   | 3 ± 1               | 3 ± 2                  | <1                     | 9 ± 2t                               |
| IRS-1%          | 0                 | 15 ± 3t             | 34 ± 3t                 | 0                     | 7 ± 2t                               |
|                 |                   | 0                   | 11 ± 2t                 | 0                     | 17 ± 3t                              |
|                 |                   |                      |                        |                        | 6 ± 2t                               |
|                 |                   |                      |                        |                        | 8 ± 2t                               |
| Oxidative stress|                   |                      |                        |                        |                                     |
| DCF (%)         | 0                 | 9 ± 1t               | 26 ± 2t                 | 0                     | 14 ± 2t                              |
|                 |                   | 34 ± 4t              | 0                      | 0                     | 22 ± 3t                              |
|                 |                   |                      | 4 ± 5t                  | <1                     |                                     |
|                 |                   |                      | 7 ± 2t                  | <1                     |                                     |
| MDA (μM)        | 0                 | 7 ± 2t               | 20 ± 4t                 | 0                     | 12 ± 2t                              |
|                 |                   | 29 ± 4t              | 0                      | 0                     | 17 ± 2t                              |
|                 |                   |                      | 3 ± 1t                  | <1                     |                                     |
|                 |                   |                      | 8 ± 1t                  | <1                     |                                     |
| Inflammatory markers|            |                      |                        |                        |                                     |
| TNFα (pg/ml)    | 18 ± 1            | 39 ± 2t             | 172 ± 4t**              | 18 ± 2                  | 23 ± 4t                              |
|                 |                   | 137 ± 5t             | 18 ± 2                  | 18 ± 3                  | 19 ± 2                              |
|                 |                   | 94 ± 4t              | 21 ± 1                  | 3 ± 1                  | 3 ± 1                               |
|                 |                   | 29 ± 3t              | 21 ± 1                  | 3 ± 1                  | 3 ± 1                               |
|                 |                   | 11 ± 1t              | 21 ± 1                  | 3 ± 1                  | 3 ± 1                               |
| IL-1β (pg/ml)   | 3 ± 1             | 18 ± 2t             | 51 ± 2t                 | 2 ± 1                  | 7 ± 2t                              |
|                 |                   | 10 ± 2t              | 2 ± 1                  | 3 ± 1                  | 3 ± 1                               |
|                 |                   | 29 ± 3t              | 2 ± 1                  | 3 ± 1                  | 3 ± 1                               |
|                 |                   | 11 ± 1t              | 2 ± 1                  | 3 ± 1                  | 3 ± 1                               |
| IL-6 (pg/ml)    | 21 ± 3            | 36 ± 3t             | 53 ± 4t                 | 19 ± 3                  | 31 ± 4t                              |
|                 |                   | 66 ± 4t              | 17 ± 2                  | 18 ± 3                  | 18 ± 2                              |
|                 |                   | 128 ± 4t             | 27 ± 3t                 | 27 ± 3t                 |                                     |
| IL-8 (pg/ml)    | 171 ± 1           | 384 ± 6t            | 915 ± 7t                | 170 ± 2                | 286 ± 3t                             |
|                 |                   | 759 ± 9t             | 167 ± 7                | 169 ± 9                | 171 ± 8                             |
|                 |                   | 335 ± 6t             | 203 ± 3t                | 203 ± 3t                |                                     |
| IL-2 (pg/ml)    | 0                 | 0                   | 0                      | 0                     | 0                                    |
| IL-10 (pg/ml)   | 2 ± 1             | 2 ± 1               | 2 ± 1                   | 2 ± 1                  | 2 ± 1                                |

Values indicate mean ± SE. Measured at 72 hours.

*P < 0.05 from baseline.
†P < 0.05 from glucose (15 mM) or palmitate (100 μM).
‡P < 0.05 from glucose (15 mM) + palmitate (100 μM).

Table 2.
Effect of hyperglycemia (glucose), hyperlipidemia (palmitic acid) on activation of human aortic endothelial cells, inflammation (proinflammatory cytokines and IL-10) and oxidative stress (DCF and MDA) and the salutary effect of α-linolenic acid.
40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet versus a High Carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet in obese, normal glucose tolerance premenopausal women [48] (see Table 3) and in obese prediabetic (Impaired Glucose Tolerant (IGT)) women and men [49] (see Table 4) in randomized, controlled clinical trials. In both studies all food was provided with weekly food pick up with daily menus and weight checks for 6 months. Although our study of IGT subjects [49] and obese, non-diabetic, women [48] had significant

| Parameters             | Baseline | 6 months | p* | Baseline | 6 months | p* | p** |
|------------------------|----------|----------|----|----------|----------|----|-----|
| Age                    | 35.9 ± 2.1| 35.4 ± 2.0| 0.8981|
| Ethnicity AA/C         | 7/5      | 10/2     | 0.3701†|
| BMI (kg/m²)            | 41.3 ± 1.8| 37.3 ± 1.9| 0.0005| 37.0 ± 1.5| 33.5 ± 1.4| 0.0005| 0.5512|
| % Weight loss          | 9.8 ± 1.4 | 9.3 ± 1.6 | 0.0005| 9.3 ± 1.6 | 9.3 ± 1.6 | 0.0005 | 0.9323|
| HOMA IR                | 4.0 ± 0.8 | 1.4 ± 0.2 | 0.0005| 3.7 ± 0.4 | 2.3 ± 0.3 | 0.0005 | 0.0033|
| ISI (Matsuda Index)    | 2.7 ± 0.5 | 6.7 ± 0.5 | 0.0005| 2.6 ± 0.3 | 3.5 ± 0.4 | 0.0005 | <0.0001|
| Beta cell function     | 4.4 ± 0.4 | 11.8 ± 2.5| 0.0005| 4.2 ± 0.4 | 6.3 ± 0.6 | 0.0005 | <0.0001|

Cardiovascular risk factors

| Parameters             | Baseline | 6 months | p* | Baseline | 6 months | p* | p** |
|------------------------|----------|----------|----|----------|----------|----|-----|
| TG (mg/dl)             | 107 ± 10 | 81 ± 2.7 | 0.0005| 102 ± 5.7| 94 ± 3.8 | 0.0117| 0.0907|
| Free fatty acids (nM)  | 0.57 ± 0.03| 0.45 ± 0.03| 0.0010| 0.56 ± 0.04| 0.73 ± 0.07| 0.0342| 0.0002|
| hCRP (mg/L)            | 5.9 ± 0.2 | 3.8 ± 0.4 | 0.0005| 5.8 ± 0.2 | 5.0 ± 0.2 | 0.0005 | 0.0003|
| E-selectin (ng/ml)     | 42.6 ± 1.5| 34.0 ± 1.3| 0.0005| 43.4 ± 1.3| 39.7 ± 1.1 | 0.0005| 0.0007|
| BP (SBP/DBP)           | 129/83 ± 1.5/1.3| 119/74 ± 1.1/1.3| 0.0005/| 128/82 ± 1.7/1.4| 75 ± 1.7/1.0 | 0.0005/| 0.1029/0.2579|

Inflammation

| Parameters             | Baseline | 6 months | p* | Baseline | 6 months | p* | p** |
|------------------------|----------|----------|----|----------|----------|----|-----|
| TNFα (pg/ml)           | 5.9 ± 1.3| 4.1 ± 0.2 | 0.0005| 6.0 ± 0.2 | 5.1 ± 0.1 | 0.0005 | <0.0001|
| IL-6 (pg/ml)           | 6.2 ± 0.2| 4.9 ± 0.2 | 0.0005| 5.8 ± 0.2 | 5.4 ± 0.1 | 0.0005 | <0.0001|

Oxidative stress

| Parameters             | Baseline | 6 months | p* | Baseline | 6 months | p* | p** |
|------------------------|----------|----------|----|----------|----------|----|-----|
| DCF (μM)               | 3.2 ± 0.1| 2.4 ± 0.1 | 0.0005| 3.2 ± 0.1| 2.9 ± 0.1 | 0.0005 | <0.0001|
| MDA (μM)               | 1.1 ± 0.06| 0.7 ± 0.05| 0.0005| 1.1 ± 0.05| 0.9 ± 0.05 | 0.0005 | 0.0004|

| % Compliance           | 94% ±1.5%| 91% ±4.8%| 0.3979|

Significant level for multiple comparison is set at P = 0.01.
*Indicates Wilcoxon Signed Rank Test.
**Indicates Wilcoxon Rank Sum Test for 6 months HP vs. HC.
†Fisher’s exact test.

AA/C, African American/Caucasian; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; hCRP, high sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; DCF, dichlorofluorescein; MDA, malondialdehyde.

Table 3.
Effect of high protein or high carbohydrate diets on weight loss, insulin sensitivity, Beta cell function, markers of cardiovascular risk factors, inflammation and oxidative stress in obese premenopausal, non-diabetic women.
weight loss (9–10%) on the HP or HC diets, in both studies the HP diet provided greater improvement in insulin sensitivity, reduced CVR factors, decreased inflammation and inflammatory cytokines, decreased oxidative stress, decreased lipid peroxidation, adipokines markers and increased incretin responses [50, 51]. The HP

| Parameters          | Baseline | 6 months  | p  | Baseline | 6 months | p  | p** |
|---------------------|----------|-----------|----|----------|----------|----|-----|
| % Remission         | 100      | 33.3      | 0.001 |
| Age                 | 43.1 ± 1.3 | 41.1 ± 1.7 | 0.96 |
| Ethnicity AA/C      | 10/2     | 9/3       |
| % Weight loss       | 9.8 ± 1.4 | < 0.001   | 11.3 ± 1.8 | < 0.001 | 0.692 |
| BMI (kg/m²)         | 40.5 ± 1.8 | 37.3 ± 1.9 | < 0.001 | 37.4 ± 1.7 | 33.8 ± 1.6 | 0.002 | 0.391 |
| % LeanBMchange      | 2.6 ± 0.4 | 0.002     | −3.0 ± 1.1 | 0.005 | 0.001 |
| % Fat BM change     | −2.5 ± 0.4 | 0.006     | −3.5 ± 0.9 | 0.007 | 0.04 |
| Insulin sensitivity |          |           |     |          |           |     |     |
| HbA1c %             | 6.0 ± 0.015 | 5.46 ± 0.12 | 0.0005 | 5.93 ± 0.12 | 5.73 ± 0.17 | 0.005 | < 0.0001 |
| HOMA IR             | 4.79 ± 0.71 | 1.58 ± 0.38 | 0.0005 | 4.74 ± 0.72 | 3.34 ± 0.78 | 0.005 | < 0.0001 |
| ISI (Matsuda index) | 2.3 ± 0.3 | 6.5 ± 1.1 | 0.0005 | 2.3 ± 0.3 | 3.2 ± 0.4 | 0.005 | 0.003 |
| Cardiovascular risk factors | | | | | | | |
| BP (SBP/DBP) | 130/81 ± 3/2 | 116/72 ± 2/2 | 0.01/0.01 | 126/81 ± 2/2 | 118/74 ± 3/3 | 0.01/0.01 | 0.73/0.77 |
| TG (mg/dl)          | 106.9 ± 10 | 69.4 ± 6.7 | 0.001 | 110.1 ± 11 | 98.7 ± 9.1 | 0.002 | 0.04 |
| LDL (mg/dl)         | 105.9 ± 4.4 | 82.4 ± 3.4 | 0.0005 | 106.2 ± 5.6 | 101.9 ± 6.2 | 0.096 | 0.037 |
| Cholesterol (mg/dl) | 165.3 ± 5.7 | 151.8 ± 5.3 | 0.0005 | 167.9 ± 6.1 | 161.7 ± 6.3 | 0.02 | 0.42 |
| HDL (mg/dl)         | 44.9 ± 1.7 | 46.3 ± 1.4 | 0.10 | 45.8 ± 2.6 | 46.2 ± 2.5 | 0.69 | 0.85 |
| FFA (mM)            | 0.74 ± 0.05 | 0.46 ± 0.04 | 0.0010 | 0.74 ± 0.04 | 0.72 ± 0.05 | 0.064 | 0.0001 |
| hCRP (mg/L)         | 9.1 ± 0.4 | 4.0 ± 0.3 | 0.0001 | 8.8 ± 0.3 | 6.4 ± 0.2 | 0.005 | 0.0003 |
| E-Selectin (ng/ml)  | 53.7 ± 1.5 | 35.0 ± 1.1 | 0.0005 | 53.4 ± 1.6 | 44.6 ± 1.7 | 0.005 | 0.0005 |
| Proinflammatory cytokines | | | | | | | |
| TNF-α (pg/ml)       | 12.8 ± 0.4 | 3.8 ± 0.2 | 0.0005 | 12.5 ± 0.4 | 9.6 ± 0.3 | 0.005 | < 0.0001 |
| IL-6 (pg/ml)        | 8.57 ± 0.34 | 4.55 ± 0.13 | 0.0005 | 8.43 ± 0.22 | 6.8 ± 0.11 | 0.0005 | < 0.0001 |
| Oxidative stress    |         |           |     |          |           |     |     |
| DCF (μM)            | 3.9 ± 0.2 | 2.5 ± 0.3 | 0.0004 | 4.0 ± 0.1 | 3.2 ± 0.2 | 0.01 | < 0.0001 |
| MDA (μM)            | 1.5 ± 0.07 | 0.6 ± 0.04 | 0.0008 | 1.5 ± 0.08 | 1.2 ± 0.04 | 0.02 | 0.0004 |

1Indicates Wilcoxon Signed Rank Test for comparison of Baseline to 6 months.
2Indicates Wilcoxon Rank Sum Test for 6 months comparison of HP vs. HC.

Table 4.
Effect of HP or HC diets on remission of prediabetes, weight loss, glucose, insulin sensitivity, cardiovascular risk factors, proinflammatory cytokines and oxidative stress.
diet caused a smaller increase in blood glucose with the MTT compared to the HC diet MTT in both obese, normal glucose tolerance premenopausal women (see Figure 1) and in obese prediabetic women and men (see Figure 2), thereby, reducing the hyperglycemia compared to that observed with a HC meal. Lipids are considered a primary risk factor for CV disease and dietary composition can affect the lipid profile and its metabolism. Our studies showed greater decrease in triglycerides in the HP diet demonstrating that increasing the protein in the diet may alter the lipid profile in a beneficial way.

Also, the HP diet subjects had an increase in percent body muscle mass and decrease in percent fat mass at 6 months, whereas, the HC diet subjects had a decrease in percent lean and fat mass. Additionally, the HP group had an increase in their resting metabolic rate (RMR) at 6 months, and an increase in the FGF21 which may be indicative of browning of fat [52, 53]. Epigenetic DNA methylation data showed a change in the methylation with remission of prediabetes in the areas of metabolism, cancer and heart related genes [54, 55].

It has been shown that protein intake by itself induces insulin release and is different in diabetic and non-diabetic individuals [56]. Our study showed a lower insulin response to the HP than the HC diet in both studies. This suggests that HP
diets may help preserve the Beta cells by increasing sensitivity and decreasing insulin load per meal. Our studies on the incretin response to HP and HC diets showed an increased release in GLP-1 and GIP with the HP diet compared to the HC diet [57]. Treatment of T2DM subjects with GLP-1 receptor agonists and DPP-4 inhibitors have been found to improve insulin sensitivity [58, 59]. This suggests that our HP diet may be beneficial in treating T2DM and have cardiovascular benefits.

This prompted us to study the effect of the HP and HC diets on remission of T2DM. Our current randomized clinical trial of Remission of Type 2 Diabetes to normal glucose tolerance (NGT) comparing a HP diet to a HC diet has demonstrated a 100% remission of Type 2 Diabetic subjects to normal glucose tolerance who were diagnosed with the past 2 years and were randomized to the HP diet for 6 months.

However, the HC diet was not very effective with only one subject having remission to normal glucose tolerance. T2D adults aged 20–65 years were randomized to a HP or HC diet for 6 months with all food provided. Caloric need for weight loss was determined by Resting Metabolic Rate (RMR) -500 calories/day. Oral Glucose Tolerance Tests (OGTT) were performed at Baseline and 6 months to determine T2D/NGT status. A Baseline glucose ≥126 mg/dl and HbA1c ≥ 6.5% and 2 hr. glucose >199 mg/dl was considered T2D and remission was a baseline glucose <126 mg/ml and HbA1c < 6.5% and 2 hr. glucose <140 mg/dl. DXA was done at baseline and 6 months to determine bone, lean and fat mass. Food pick up and menus were provided weekly for 6 months along with weekly weight checks.

The T2D subjects on HP diet had 100% remission to NGT while the HC diet subjects had 33% remission. Both diet groups had significant weight loss (HP =15.4 ± 5 lb., HC = 19.9 ± 5 lb), improvement in insulin sensitivity determined by HOMA IR [HP (BL 5.3 ± 0.29; 6 months 2.1 ± 0.13)], [HC (BL 5.2 ± 0.27; 6 months 4.4 ± 0.26)] and decrease in HbA1c [HP (BL 7.7 ± .05; 6 mo 5.6 ± .02)], [HC (BL 7.8 ± .04; 6 mo 6.6 ± .06)] and blood pressure improvement S/D [HP (BL 129/85, 6 months 117/78)], [HC (BL 130/85; 6 months 117/78)]. The HP group had a 2.7% ± 0.4% increase in lean body mass and 2.9 ± 0.4% decrease in fat mass while the HC group had a 1.9% ± 0.3 and 3.3 ± 0.9% decrease in lean and fat mass, respectively. The HP diet provided greater improvement in insulin sensitivity, reduced CVR factors, decreased inflammation and inflammatory cytokines, decreased oxidative stress, decreased lipid peroxidation, adipokines markers and increased incretin responses than the HC diet. Both diets resulted in weight loss, improvement in glucose tolerance and insulin sensitivity but only the HP diet produced 100% remission of T2D to NGT [60].

4. Discussion

High glucose levels initiates inflammatory markers, ROS and hyperglycemia induced pathways in both T lymphocytes and HAEC. Hyperglycemia induced pathways of endothelial damage can activate ERK1/2MAPK cascade via PKC or Advanced Glycation End (AGE) products [4, 25]. High glucose can induce formation of AGE products which are proteins or lipids which become glycated due to exposure to glucose. These AGE products are implicated in aging and many degenerative diseases such as diabetes, atherosclerosis, kidney disease and possibly Alzheimer’s disease [61–67]. The glycation of various protein and lipids causes improper function of these molecules, for example, inactivation of anti-aging genes critical to prevent hyperglycemia and hyperlipidemia induced inflammation [68, 69]. We have shown that with remission of prediabetes and better glucose control numerous genes have changes in DNA methylation affecting gene
expression and translation of which any of these genes are involved in insulin signaling, cardiovascular disease and inflammation [55]. The effects of hyperglycemia and hyperlipidemia we have shown on the T-lymphocytes will affect the immune system and its function as well as the endothelial cells involved in cardiovascular function. The decrease in inflammation with the decrease in blood glucose and lipids in subjects with the HP diet correlates with the effects of glucose and fatty acids on inflammation and oxidative stress we observed in vitro studies of the T-lymphocytes and aortic endothelial cells. This demonstrates the effects of the high glucose and lipids on cells and the whole body. Thus, indicating the importance of good glucose control in diabetic subjects as well as prediabetic and normal subjects to prevent the inflammatory response. Figure 3 is a diagram of the effects of high glucose on cells and tissues which can be controlled with normal glucose and free fatty acids.

Our previous studies of subjects with Adult Respiratory Distress Syndrome (ARDS) showed the high levels of inflammatory markers. [70, 71]. Reports from the CDC show the deleterious effects COVID-19 has on diabetic subjects indicating that the combined inflammation of the virus plus the high inflammatory markers in diabetic subjects is very detrimental to the subjects. Thus, good glucose control could help decrease the high inflammatory markers observed with the COVID-19.

5. Conclusions

Approximately 65% of patients with T2DM die as a result of cardiovascular disease with hyperglycemia and hyperlipidemia being important risk factors for cardiovascular diseases. Both Type 2 diabetes (T2DM) and atherosclerosis are considered to be inflammatory processes. Human T-lymphocytes (T-cells) and Human Aortic Endothelial cells (HAEC) have been shown to be components of plaque formation in atherosclerosis. T cells and HAEC are unique in that in their naive state they have no insulin receptors responsive to insulin but become activated in the presence of in vitro and in situ hyperglycemic conditions such as diabetic and/or hyperlipidemia of saturated fatty acids (SFA). The unsaturated fatty acid (UFA) α-linolenic acid partially inhibits the activation of T cells induced by either glucose or SFA palmitate alone or in combination. Thus, linolenic acid may serve as a
protective mechanism against the deleterious effects of high glucose and SFAs in human T-cells and reduce the inflammatory process observed with high blood glucose and high saturated fatty acid foods.

A diet which causes a lower blood glucose and lipids after ingestion is beneficial in controlling glucose and lipids as we have shown with the High Protein Diet. The HP diet resulted in 100% remission of pre-diabetes to normal glucose tolerance while the HC diet resulted in only 33% remission. These results show that high efficacy can be achieved with dietary modification if parameters are rigorously controlled and monitored. The HP group had greater improvement in insulin sensitivity, greater reduction in CVR factors, oxidative stress (ROS) and inflammation than the HC diet group. The HP diet prediabetes group percent lean body mass (LM) increased while percent body FM was decreased; whereas, the HC diet group lost both percent LM and FM. Since all subjects were minimally physically active and there was no physical activity modification during the 6 months on the diets, we were able to study the direct effect of the HP versus HC diets. The HC group sustained higher glucose and insulin levels with both the OGTTs and MTTs compared with the HP diet group after 6 months on the diet. The greater insulin response with the HC diet likely equates to greater stress on β cells. The higher sustained glucose elevation with ingestion of glucose or higher glycemic foods as in the HC diet correlates with increased oxidative stress and inflammation in the HC group compared with the HP group. Antioxidant enzymes induced by repeated intake of excess energy in the form of high-fat, HC diets are not sufficient to block oxidative stress and inflammation in healthy human subjects [72]. Thus, the fact that our HP diet had a significantly greater reduction in blood glucose, free fatty acids, ROS and inflammation markers than the HC diet in prediabetes and normal subjects demonstrates the importance of maintaining good glucose control and is of great health importance.

Author details

Frankie B. Stentz
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA

*Address all correspondence to: fstentz@uthsc.edu

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References

[1] (CDC) CfDC. National Diabetes Statistics Report, 2018. www.cdc.gov/diabetes/data/statistics/2018StatisticsReport. 2018.

[2] DCCT. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med. 1993;329(977–86).

[3] Haffner S. Epidemiological Studies on the Effects of Hyperglycemia and Improvement of Glycemic Control on Macrovascular Events in Type 2 Diabetes. Diabetes Care. 1999;22(3):C54-C6.

[4] Stern M. Natural History of Macrovascular Disease in Type 2 Diabetes. Role of Insulin Resistance. Diabetes Care. 1999;22(3):C2-C5.

[5] Haffner S. Hyperglycemia as a Cardiovascular Risk Factor. Am J Med. 2003;115(Suppl 8A):6S–11S.

[6] (UKPDS) UPDSG. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment, and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). Lancet Diabetes Endocrinol. 1998;352(837–53).

[7] Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, and Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab. 2008;93(5):1541–52.

[8] Creager M. Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part 1. Circulation. 2003;108(1527–32).

[9] Dandona P, Aljada A, Chaudhuri A, and Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord. 2004;5(3):189–97.

[10] Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88(2):E14–22.

[11] Schnyder B, Pittet M, Durand J, and Schnyder-Candrian S. Rapid effects of glucose on the insulin signaling of endothelial NO generation and epithelial Na transport. Am J Physiol Endocrinol Metab. 2002;282(1):E87–94.

[12] Stentz FB, Umpierrez GE, Cuervo R, and Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53(8):2079–86.

[13] Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.

[14] Helderman JH. Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. J Clin Invest. 1981;67(6):1636–42.

[15] Stentz FB, and Kitabchi AE. De novo emergence of growth factor receptors in activated human CD4+ and CD8+ T lymphocytes. Metabolism. 2004;53(1):117–22.

[16] Stentz FB, and Kitabchi AE. Activated T lymphocytes in Type 2 diabetes: implications from in vitro studies. Curr Drug Targets. 2003;4(6):493–503.

[17] Stentz FB, and Kitabchi AE. Hyperglycemia-induced activation of human T-lymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species.
Stentz FB, and Kitabchi AE. Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation. Biochem Biophys Res Commun. 2006;346(3):721–6.

Stentz FB, and Kitabchi AE. Transcriptome and proteome expression in activated human CD4 and CD8 T-lymphocytes. Biochem Biophys Res Commun. 2004;324(2):692–6.

Kitabchi AE, Stentz FB, and Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun. 2004;315(2):404–7.

Bar RS, Boes M, Dake BL, Booth BA, Henley SA, and Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. Am J Med. 1988;85(5A):59–70.

Chisalita SI, and Arnlqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab. 2004;286(6):E896–901.

Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, and King GL. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993;42(1):80–9.

Gosmanov AR, Stentz FB, and Kitabchi AE. De novo emergence of insulin-stimulated glucose uptake in human aortic endothelial cells incubated with high glucose. Am J Physiol Endocrinol Metab. 2006;290(3):E516–22.

Sheetz MJ, and King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288(20):2579–88.

Srinivasan S, Hatley ME, Reilly KB, Danziger EC, and Hedrick CC. Modulation of PPARalpha expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion. Arterioscler Thromb Vasc Biol. 2004;24(5):851–7.

Aljada A, Ghanim H, Assian E, and Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism. 2002;51(4):487–91.

Stentz FB, and Kitabchi AE. Transcriptome and proteome expressions involved in insulin resistance in muscle and activated T-lymphocytes of patients with type 2 diabetes. Genomics Proteomics Bioinformatics. 2007;5(3-4):216–35.

Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, and Creager MA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97(17):1695–701.

Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, and Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006;55(1):202–8.

Stentz FB, Eastman, A., Christman, J.V. Hyperglycemia and Hyperlipidemia Induced Inflammation and Oxidative Stress in Human T Lymphocytes and Salutary Effects of ω-3 Fatty Acid. SunKrist J Diabet Clin Care. 2020;1(1–9).

Grundy SM, and Denke MA. Dietary influences on serum lipids and
lipoproteins. *J Lipid Res.* 1990;31(7): 1149–72.

[33] Roden M, Price TB, Perseghin G, Petersen KP, Rothman DL, Cline GW, and Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. *J Clin Invest.* 1996;97(12):2859–65.

[34] Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes.* 1997;46(1):3–10.

[35] Koska J, Ozius MK, Deer J, Kurtz J, Salbe AD, Harman SM, and Reaven PD. A human model of dietary saturated fatty acid induced insulin resistance. *Metabolism.* 2016;65(11):1621–8.

[36] Stentz FB, AA, Kitabchi AE. Effect of Saturated Fatty Acids and Unsaturated Fatty Acids on Fatty Acid Receptors and Transport Proteins in Aortic Endothelial Cells. *J Investig Med.* 2008;56(359.

[37] Diabetes Prevention Program. The Diabetes Prevention Program (DPP) Research Group. Reduction in the incidence of Type 2 Diabetes with lifestyle intervention or metformin. *NEJM.* 2002;346(39):393–403.

[38] DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. *N Engl J Med.* 2011;364(12):1104–15.

[39] Franz MJ, Powers MA, Leontos C, Holmmeister LA, Kulkarni K, Monk A, Wedel N, and Gradwell E. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. *J Am Diet Assoc.* 2010;110(12):1852–89.

[40] Larsen RN, Mann NJ, Maclean E, and Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. *Diabetologia.* 2011;54(4):731–40.

[41] Alford BB, Blankenship AC, and Hagen RD. The effects of variations in carbohydrate, protein, and fat content of the diet upon weight loss, blood values, and nutrient intake of adult obese women. *J Am Diet Assoc.* 1990;90(4):534–40.

[42] McManus K, Antinoro L, and Sacks F. A randomized controlled trial of a moderate-fat, low-energy diet compared with a low fat, low-energy diet for weight loss in overweight adults. *Int J Obes Relat Metab Disord.* 2001;25(10):1503–11.

[43] Larsen TM, Dalskov SM, van Baak M, Jebb SA, Papadaki A, Pfeiffer AF, Martinez JA, Handjiava-Darlenska T, Kunesova M, Pihlsgard M, et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. *N Engl J Med.* 2010;363(22):2102–13.

[44] Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr., Brehm BJ, and Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch Intern Med.* 2006;166(3):285–93.

[45] Boden G, Sargrad K, Homko C, Mozzoli M, and Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. *Ann Intern Med.* 2005;142(6):403–11.

[46] Eisenstein J, Roberts SB, Dallal G, and Saltzman E. High-protein weight-loss diets: are they safe and do they work? A review of the experimental and epidemiologic data. *Nutr Rev.* 2002;60(7 Pt 1):189–200.

[47] Bray GA, Smith, S.R., de Jonge, L. Effect of dietary protein content on weight gain, energy expenditure, and body composition during overeating: a
randomized controlled trial. *JAMA.* 2012;307(1):47–55.

[48] Kitabchi AE, Stentz FB, McDaniel KA, Wan JY, Nyenwe E, and Sands CW. Effects of high-protein versus high-carbohydrate diets on markers of beta-cell function, oxidative stress, lipid peroxidation, proinflammatory cytokines, and adipokines in obese, premenopausal women without diabetes: a randomized controlled trial. *Diabetes Care.* 2013;36(7):1919–25.

[49] Stentz FB, Brewer A, Wan J, Garber C, Daniels B, Sands C, and Kitabchi AE. Remission of pre-diabetes to normal glucose tolerance in obese adults with high protein versus high carbohydrate diet: randomized control trial. *BMJ Open Diabetes Res Care.* 2016;4(1):e000258.

[50] Stentz F, Kimeish, O, Kitabchi, A. Effect of High Protein vs High Carbohydrate Diets on Incretins, Satiety and Cardiovascular Factors. *Diabetes.* 2014;62: (Suppl 1):1825.

[51] Stentz FB, Ammons, A., Sands, C. Incretin and Cardiovascular Effects of Weight Loss and Remission of Prediabetes. *Diabetes.* 2018;67(Suppl 1):544.

[52] Daniels B, Stentz, FB. Efect of Diet Composition on Remission of Prediabetes and Metabolic Parameters. *J Investig Med.* 2016;65(2):501.

[53] Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdegue F, Wu J, Khartonovnov A, Flier JS, Maratos-Flier E, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev.* 2012;26(3):271–81.

[54] Stentz F, Garber, C., Kitabchi, A., Efficacy of High Protein vs. High Carbohydrate Diet on Remission of Impaired Glucose Tolerance (IGT) to Normal Glucose Tolerance (NGT). *Diabetes.* 2015;64(Suppl 1):512.

[55] Stentz FB, Patel, D. Epigenetic Changes in DNA Methylation with Remission of Prediabetes. *Diabetes.* 2017;66(1):85.

[56] Nuttall FQ, Mooradian AD, Gannon MC, Billington C, and Krezowski P. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. *Diabetes Care.* 1984;7(5):465–70.

[57] Stentz FB, Mikhael, A., Kineish, O, Christman, J.V, Sands, C. Incretins and Cardiovascular Effects of Weight Loss and Remission of Prediabetes. *J Diabet Clin Studies (JDCS).* 2020.

[58] American Diabetes Association. Standard of Medical Care in Diabetes. *Diabetes Care.* 2018;41(Suppl 1):S1-S7.

[59] Eng C, Kramer CK, Zinman B, and Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. *Lancet.* 2014;384(9961):2228–34.

[60] Stentz FB, Tucker, S., Sands, C. Remission of Type 2 Diabetes and Improvement of Metabolic Factors with a High Protein Diet. *Diabetes.* 2020; Diabetes website(1862.

[61] Goldin A, Beckman JA, Schmidt AM, and Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation.* 2006;114(6):597–605.

[62] Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, and Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. *Free Radic Res.* 2013;47 Suppl 1(3–27.
Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, Gugliucci A, and Kapahi P. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. *Cell Metab.* 2018;28(3):337–52.

Yan SF, D’Agati V, Schmidt AM, and Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. *Curr Mol Med.* 2007;7(8):699–710.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes.* 2005;54(6):1615–25.

Prasad A, Bekker P, and Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. *Cardiol Rev.* 2012;20(4):177–83.

Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, and Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. *Neurobiol Aging.* 2011;32(5):763–77.

Martins IJ. Anti-Aging Genes Improve Appetite Regulation and Reverse Cell Senescence and Apoptosis in Global Populations. *Advances in Aging Research.* 2016;5(9–26).

Martins IJ. Single Gene Inactivation with Implications to Diabetes and Multiple Organ Dysfunction Syndrome. *J Clin Epigenet.* 2017;3(3–24).

Stentz F, Headley, S., Tolley, E., Meduri, G.U.,. The Interaction of Proinflammatory Cytokines (PIC) and NF-kB in Acute Respiratory Distress Syndrome (ARDS) and Response to Treatment with Methylprednisolone (MP). *First International Congress on Cytokines/Chemokines in Infectious Diseases.* 1999;Bethesda, MD(American Association of Immunologists).